In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MediciNova gets two cardio compounds from Meiji Seika Kaisha

Executive Summary

MediciNova has gained rights to two of Meiji Seika Kaisha's (infectious disease and neurological pharmaceuticals) small-molecule anti-thrombotic compounds. MN447 is in development for blood clot formation and MN462 for lysis; both have the potential for use in several thrombotic disorders. The worldwide license excludes Japan, Bangladesh, Brunei, Cambodia, the People's Republic of China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies